oncoprime - drug screening platform using patient derived cells
TRANSCRIPT
-
Adopt cutting edge approaches in
Phenotypic Drug Discovery
What can be a better model than diseased cells...when that's what we intend to treat !
Organotypic, 3D cell cultureSpheroid, Monolayers & Co-culture
Diseased cells
from patient
samples
Cell lines with aberrant mutations
not found in primary tumor
Target based assays
ignore the big picture
Will your screening assay system translate to clinics ?Introducing...
Highly complex
More clinically relevant Less physiological
Simple
Early
passage
>30
passages
SAARUMSCIENCES
Phenotypic Platforms for Drug & Biomarker Discovery
Do you really know what cells you are working with ?
Recent studies suggest that only 40% of established cell lines are useful for drug discovery.
Historically most drugs were discovered by phenotypic screens only
Primary cell based phenotypic screening is the way to go...
OncoPrimeTM
OncoPrimeTM
https://www.facebook.com/saarumsciences
https://www.linkedin.com/company/saarum-sciences
http://twitter.com/saarumsciences
-
We have a wide range of technology platforms available...
We Offer Comprehensive Drug Discovery Services...
Multicolor Flow cytometryFluorescent microscopyConfocal microscopyFACS cell sortingMagnetic beads
SNP genotyping / SNP arraysNext Generation Sequencing
BioinformaticsPathway / Network
Systems biology
BiacoreCDHPLCGCMSLC-MALDI-TOFX-Ray diraction
FISHIHC
IHC-FrELISA
Karyotyping
Sterile fresh cancertissues are obtained at the biobank afterEC approvals andinformed consent
CustomizedPrimary CellPhenotypic Assayswith completeOMICs data ready for research
Explants or Primary Cells
are derived from thetissues to obtain a
heterogeneous culture
Cells are characterized
for required parametersincluding complete
pathology reports andused for desired assay(s)
1
2
3
4
OncoPrimeTMScreen new chemical or biological entities
for optimal efficacy
Systematically screen cancers prevalent in India against a 'pill box'
Repurpose drugs / combinations to derive novel IP and get to market faster
Investigate unique tumor characteristics of Indian patients by gene profiling
Generate patient response data by combining in vitro assays with clinical outcomes
Saarum Sciences Capabilities
0
20
40
60
80
100
Targetidentification and selection
HTS Preclinicaland
Phase Istudies
Phase IIstudies
Phase IIIstudies
Diseaserelevant
biologicalhit
Leadoptimization
inin vitro
clinical trials
Req
uir
ed R
&D
pro
gram
mes
an
d r
esou
rces
(US$
)Phenotypic drug discovery using patient derived samples
Impact of
One approved drug
-
can be used in multitude of ways...
Use our platforms to accelerate your drug discovery pipeline...
In vitro phenotypic assaysDerivation of cell lines, engineered platformsGeneration of tissue arrays, gene, protein arraysGeneration of mouse & zebrafish xenografts
Tumor Milieu - with CAFs- with Immune cells- Tumor explants
EMT&
MET
CancerStem cells
Radiationresistant
tumor cells
Radiationsensitive
tumor cells
Chemoresistanttumor cells
NovelBiomarker
Targets
Identify resistance
mechanisms
The cells are well characterized including morphology, cell surface markers and mutation profileFunctional assays like migration, invasion, sphere forming assays etc. can be performedYour molecules could be screened across these phenotypes for target discovery, MOA eludication or in vitro effcacy asessment or drug repurposing or indication selection
Versatile phenotypes on offer
OncoPrimeTM
OncoPrimeTM
Primary cell phenotypic screening assays forphenotypic drug discovery (PDD)
Disease modeling & MoA studies using normal and diseased primary cells, CSCs/CTCs, hESCs/iPSCs etc
Novel disease models engineered from primary cells(EMT/MET - available; others in pipeline)
Toxicology assessment using hESCs and hiPSCs
Fresh tissues available across variety of indications &pathologies; Oncology, CNS, CVS, hematology, immunology, dermatology etc
FFPE tissue collection for retrospective studies e.g. disease recurrence
Overview of fresh tissue collection @ 1 site / 1 yr
Breast - Malignant
Uterus - Normal
Prostate
Colon
Thyroid
Brain - Malignant
Breast - Malignant
BrainMalignant
Uterus - Normal
Prostate
Colon
Thyroid
Central Nervous System
RespiratorySystem
Immunology
Hematology
BreastNormal
GastrointestinalSystem
Genitourinary System
-
Fast track your drug development process with
Primary Cell Based Phenotypic Assays
Primary cell panels derived from patient samples for various tumor types
Short term cultures retaining clinically relevant features of the disease including tissue heterogeneity, proliferation rate and gene expression profiles
Address clinical variability such as different disease stages spanning from pre-cancerous, benign lesions to metastatic cancer
Well characterized for driver mutations relevant to patient population
Associated medical records (EMR) of the patient for additional information
Why choose Saarum Sciences...
Advantages of using
Saarum Sciences is an innovative biotech company developing & employing novel primary cellbased platforms for phenotypic drug & biomarker discovery applications
We have several decades of proven global drug discovery and cell biology expertise across all major therapeutic areas
Ongoing collaborations with a wide variety of clientele such as scientific organizations, pharmaceutical & biotech sector, research institutes and CROs
Saarum Sciences Pvt. Ltd.,
Indian Institute for Chemical Technologies
Tarnaka, Hyderabad 500007, India.
Tel: +91-9704600283, +91-40-20084362
Email: [email protected]
Website: http://www.saarum.com
SAARUMSCIENCES
Phenotypic Platforms for Drug & Biomarker Discovery
Saarum has a steady inflow of freshly procured & well-annotated patient-derived primary samples through its sister concern Sapien Biosciences
Sapien Biosciences, in partnership with Apollo Hospitals (India's largest healthcare provider), has set up India's largest state-of-the-art bio-repository that is systematically acquiring & archiving patient samples under appropriate ethical consent & regulatory approvals
OncoPrimeTM
Request for information: